主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LGVN
#538
Longeveron Inc. Common Stock
0.973
5
USD
+20.33%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
+20.33%
每月变动
+70.40%
6个月变化
+70.40%
年变化
+70.40%
前一天收盘价
0.809
0
Open
0.973
5
Bid
0.973
5
Ask
0.976
5
Low
0.973
5
High
0.973
5
交易量
14
市场
股票
医疗保健
LGVN
Open full chart
Financials
Overview
声明
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
532.65 K
616.3 K
1.03 M
13.47 M
—
Valuation ratios
Enterprise value
—
—
—
58.28 M
181.74 M
Price to earnings ratio
—
—
—
-0.66
14.36
Price to sales ratio
—
—
—
6 806.57
20.94 K
Price to cash flow ratio
—
—
—
1 174.02
2 967.23
Price to book ratio
—
—
—
743.88
1 108.52
Enterprise value to EBITDA ratio
—
—
—
-3.68
-10.35
Profitability ratios
Return on assets %
0.4
0.69
1.77
0.63
1.16
Return on equity %
0.46
0.92
3.18
0.73
1.6
Return on invested capital %
418.04
1 983.57
900.55
949.13
1 407.92
Gross margin %
45.18
40.67
31.17
78.76
297.35
Operating margin %
1 336.6
1 476.51
2 966.01
690.72
9 113.8
EBITDA margin %
-1 336.6
-1 476.51
-2 867.28
-661.45
-8 835.45
Net margin %
1 305.13
1 541.33
3 020.17
668.9
8 848.9
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
13.06
4.17
1.5
7.6
18.73
Inventory turnover
—
—
—
—
—
Asset turnover
0.03
0.03
0.04
0.13
0.06
Solvency ratios
Debt to assets ratio
0
0.08
—
—
—
Debt to equity ratio
0
0.11
—
—
—
Long term debt to total assets ratio
0
0.02
—
—
—
Long term debt to total equity ratio
0
0.03
—
—
—
Per share metrics
Operating cash flow per share
—
6.66
8.74
0
0
EBIT per share
—
-8.6
-9.68
-0
-0
EBITDA per share
—
-8.6
-9.35
-0
-0
Total debt per share
—
1.1
—
—
—
Cash per share
—
9.37
2.44
0
0
Net current asset value per share
—
9.67
2.69
0
0
Tangible book value per share
—
8.63
2.05
0
0
Working capital per share
—
7.35
0.9
0
0
Book value per share
—
9.78
3.1
0
0
新闻
Longeveron完成1500万美元融资 运营资金延长至2026年第四季度
Longeveron closes $15 million financing, extends runway to 4Q26
Longeveron获得1500万美元融资,试验结果达标可再获1500万美元
Longeveron secures $15M financing, eyes $15M more on trial results
Longeveron在期刊上发布2b期干细胞试验结果
Longeveron publishes phase 2b stem cell trial results in journal
Longeveron任命Stephen Willard为新CEO,迎接关键试验结果
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results
Longeveron receives Japanese patent for stem cell potency assay methods
Longeveron为关键性HLHS疗法数据与FDA会面做准备
Longeveron prepares for pivotal HLHS therapy data with FDA meeting
Longeveron获得针对女性性功能障碍的干细胞疗法专利